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Despite much evidence on epigenetic abnormalities
in cancer, it is currently unclear to what extent epige-
netic alterations can be associated with tumors’
clonal genetic origins. Here, we show that the pros-
tate intratumor heterogeneity in DNA methylation
and copy-number patterns can be explained by a
unified evolutionary process. By assaying multiple
topographically distinct tumor sites, premalignant
lesions, and lymph node metastases within five
cases of prostate cancer, we demonstrate that both
DNA methylation and copy-number heterogeneity
consistently reflect the life history of the tumors.
Furthermore, we show cases of genetic or epigenetic
convergent evolution and highlight the diversity in
the evolutionary origins and aberration spectrum
between tumor and metastatic subclones. Impor-
tantly, DNA methylation can complement genetic
data by serving as a proxy for activity at regulatory
domains, as we show through identification of
high epigenetic heterogeneity at androgen-recep-
tor-bound enhancers. Epigenome variation thereby
expands on the current genome-centric view on
tumor heterogeneity.798 Cell Reports 8, 798–806, August 7, 2014 ª2014 The AuthorsINTRODUCTION
Prostate adenocarcinoma is the most common cancer among
men and globally causes over 250,000 deaths every year
(Bray et al., 2013). Genetically, it is strongly dominated by
copy-number and other structural alterations rather than by
nonsynonymous point mutations (Baca et al., 2013; Barbieri
et al., 2012; Berger et al., 2011; Grasso et al., 2012; Shen
and Abate-Shen, 2010; Taylor et al., 2010; Weischenfeldt
et al., 2013). Moreover, aberrant DNA methylation patterns
are universally found in prostate tumors and are known to
frequently affect genes involved in hormonal response, cell
cycle control, and DNA damage repair (Bo¨rno et al., 2012; Ko-
bayashi et al., 2011; Li, 2007; Nelson et al., 2009). In light of the
recent discoveries of extensive genetic intratumor heterogene-
ity (Almendro et al., 2014; Gerlinger et al., 2012; Johnson et al.,
2014; Landau et al., 2013; Lohr et al., 2014; Navin et al., 2011;
Navin, 2014; Nik-Zainal et al., 2012; Sottoriva et al., 2013), we
analyzed how methylomes vary within the same prostate tumor
and how such variation is associated with the diversity in
genomic alterations and the evolutionary history of the tumor.
Given that prostate cancers are dominated by structural
alterations and that intratumor copy-number and mutational
diversity are highly correlated during tumor evolution (Gerlinger
et al., 2014), we focused on copy-number alterations as
a measure of genomic intratumor variability. To simulta-
neously study methylome and copy-number patterns in multiple
Figure 1. Subclonal Cell Populations Differ in Their Genetic and Epigenetic Profiles
(A) Unsupervised hierarchical clustering of intratumoral methylation patterns for cases 1–5 (left to right). Tissue types from each individual are color coded with
green (normal [NP]), orange (premalignant lesions [PIN]), blue (primary tumor [TU]), and red (lymph node metastasis [LNM]). Rows of the heatmaps display the
methylation levels of the patientwise top 1%CpG sites (n = 4,457) with the greatest intratumoral DNAmethylation variability (range). Blue indicates low, and yellow
represents high methylation level (from 0% to 100%).
(B) Copy-number alteration profiles from different regions of the same tumor (cases 1–5; left to right). Deletions (blue) and amplifications (red) are shown for
chromosomes 1–X. Specimens are ordered according to the result of the unsupervised hierarchical cluster analysis of the methylation data (A).spatially separated regions of a tumor, we used Illumina Hu-
manMethylation450 BeadChip arrays, which not only target
more than 450,000 CpG sites covering 99% of RefSeq genes
but can also be employed to detect copy-number alterations
with the sensitivity of SNP arrays (Feber et al., 2014; Oakes
et al., 2014; Sturm et al., 2012). In total, the analyzed sample
cohort consisted of multiple geographically distinct primary
tumor sites (TU; n = 10), premalignant lesions (PIN; n = 2),
lymph node metastases (LNM; n = 3), and matched normal
prostate epithelium (NP; n = 1) from each five patients with
aggressive prostate cancer (Table S1). Out of these in total 80
specimens, 72 were used for subsequent analyses; the others
were excluded due to low tumor content or inconclusive
copy-number profiles (Figure S1).
RESULTS
Extensive Genetic and Epigenetic Heterogeneity
between Different Regions of the Same Tumor
We first performed unsupervised hierarchical clustering of both
DNA methylation and copy-number patterns. This analysis
showed that specimens of the same patient were generally
more similar to each other than those from different individuals
(Figures S2A and S2B), in line with the previously described
interindividual heterogeneity of prostate cancer metastases
(Aryee et al., 2013; Drake et al., 2013; Liu et al., 2009). In addi-tion, the presence of shared methylation patterns and chromo-
somal breakpoint profiles between all tumor regions of a
patient indicated a monoclonal origin in all five cases. Analysis
of intratumoral DNA methylation and copy-number patterns
further demonstrated the presence of multiple subclonal cell
populations that were characterized by both distinct copy-
number as well as DNA methylation profiles (Figure 1). In
contrast to copy-number gains and DNA hypomethylation, we
found copy-number losses and DNA hypermethylation events
to be more clonal, i.e., more frequently shared between tumor
sites (Figures S2C and S2D). Genes affected by clonal dele-
tions or hypermethylation events included known tumor sup-
pressor genes, e.g., PTEN, TP53, or GSTP1, respectively (Fig-
ure S2E), suggesting that these alterations occurred earlier
during prostate cancer pathogenesis. Of the 47 genes with
ubiquitous promoter hypermethylation in all cases, 16 (34%)
were associated with transcriptional repression in another
cohort of prostate cancer (Figure S2F). Importantly, whereas
events found across all tumor sites also appeared dominant
in individual regions (Figure S2G), a dominant event in a single
specimen did not necessarily predict presence across the
entire tumor bulk (Figure S2H). Together, these data show
the extensive spatial DNA methylation and copy-number het-
erogeneity in prostate cancers of a monoclonal origin and the
utility of multiregion analysis for the identification of clonal
DNA methylation alterations.Cell Reports 8, 798–806, August 7, 2014 ª2014 The Authors 799
Figure 2. Unified Evolution of Methylation and Copy-Number Patterns
(A) Phylogenetic reconstruction showing clonal relationships in case 5 inferred from DNA methylation (left), copy-number (center) distance matrices, or
chromosomal breakpoint profiles (right). Tissue types are color coded with green (NP), orange (PIN), blue (TU), and red (LNM).
(B) Illustration of genetic and epigenetic distance matrix comparison. Heatmaps show the Euclidean distance for all specimens of case 5 based on copy-number
(left) and DNA methylation (right) patterns. Diagonal elements of the resulting correlation matrix were used to estimate the samplewise genetic and epigenetic
correlation shown in (C). Colors represent Euclidean distance from low (blue) to high (red).
(C) Distribution of the correlation between DNA methylation and copy-number distance matrices for all specimens.
(D) Casewise mean correlation between genetic and epigenetic copy-number distance matrices (dotted lines) compared to the cumulative null distributions
(sigmoidal curves) obtained by randomly permuting sample labels and repeating the steps 100,000 times. Color code indicates case number: one (red), two
(yellow), three (blue), four (green), and five (purple).Epigenetic Alterations Can Be Associated with the
Clonal Architecture of Tumors
To study the association of genetic with epigenetic changes
during tumor evolution, we inferred phylogenetic relationships
based on either chromosomal breakpoint profiles (Letouze´
et al., 2010) or based on pairwise distances of copy-number
or methylation profiles as previously performed for copy-num-
ber or mutation data (Navin et al., 2011; Xu et al., 2012). DNA
methylation and copy-number-derived phylogenetic tree topol-
ogies displayed high visual overlap (shown for case 5 in Fig-
ure 2A and for all others in Figure S3A). To better assess the
similarity of intratumoral copy-number and DNA methylation
patterns, we calculated the Pearson correlation coefficient be-
tween genetic and epigenetic distance matrices, which formed
the basis of the inferred phylogenies (Figure 2B). Using this800 Cell Reports 8, 798–806, August 7, 2014 ª2014 The Authorsapproach for the five cases, we observed a strong linear rela-
tionship between genetic and epigenetic distances (median
R = 0.9 of all 72 specimens; Figures 2C and S3B). Of note,
we obtained consistent results also when using all CpGs, not
only the most variable (median R = 0.85; Figure S3C), or after
removal of all CpG sites within nondiploid copy-number regions
(median R = 0.84; Figure S3D). We thus excluded that the high
association between methylation and copy-number patterns is
an artifact of a detection bias. To determine an empirical p
value for the observed correlation, we compared the patient-
wise mean correlation of genetic and epigenetic patterns
against the null distributions obtained by randomly permuting
sample labels. For all five cases, we found a highly significant
association (p < 1 3 105; Figure 2D). Together, these data
indicate that genome and epigenome diversity are not mutually
exclusive but can be explained by a unified evolutionary
process.
Diversity in Metastatic Origin and Convergent
Tumorigenic Processes
To further investigate the phylogenetic relationship of tumor
subclones and to gain valuable clinical insight into the disease
origin and progression for each of the five cases, we recon-
structed consensus phylogenies based on both genetic and
epigenetic data sets (Figure 3A). This combination gave more
robust evolutionary models than the inferred clonal relation-
ships based on genetic or epigenetic data sets alone (Fig-
ure S3E), displaying the utility of both measurements for dis-
tance-based evolutionary analyses. Consensus phylogenies
demonstrated branched rather than linear evolutionary tumor
growth, with clonal diversity not only within primary tumors
but also between premalignant, primary, and metastatic sites.
PIN lesions were either closely related to the normal prostate
epithelium or diverged after the tumor bulk had already been
established. Metastases originated from a shared subclonal
ancestor (cases 1 and 2) or emerged independently from
distinct tumor branches (cases 3 and 4). Critically, dissemina-
tion of metastasizing subclones was not always one of the lat-
est events (like in case 1) but could occur earlier with respect to
the emergence of the other primary tumor subpopulations
(cases 2–5). Most noteworthy, the clone that gave rise to
metastasis LNM_1 in case 4 lacked several of the chromo-
somal deletions otherwise found across all other tumor regions
(Figure 1B), suggesting that the dissemination occurred before
the two major tumor branches had evolved (Figure 3A). In addi-
tion, metastases always carried unique alterations not found in
the primary tumor bulk and metastasis-specific aberrant
methylation events frequently colocalized with genes involved
in metastasis-associated processes, indicating that further
genetic and epigenetic events were required for successful
niche adaptation (Figure S4). Examination of phylogenetic rela-
tionships and underlying copy-number and DNA methylation
profiles showed that phylogenetically distant tumor populations
could independently acquire convergent copy-number states.
For example, tumor subclonal cell populations TU_9 and
TU_10 from case 4 autonomously gained large parts of chro-
mosome 8 encoding the MYC oncogene (Figure 3B). Similarly,
metastasis LNM_3 and primary tumors TU_8 and TU_9 (case 4)
independently lost methylation at hundreds of corresponding
CpG sites (Figure 3C) without any signs of convergent evolution
at the copy-number level. Altogether, detailed reconstruction of
genetic and epigenetic histories revealed independent and
convergent tumorigenic evolutionary processes and facilitated
identification of the evolutionary origins of metastases and tu-
mor subpopulations.
Intratumor DNA Methylation Heterogeneity
Predominantly Occurs at Prostate-Specific Gene
Regulatory Elements
Given the extensive DNA methylation heterogeneity, we asked
whether these variable patterns were equally distributed across
the genome or were enriched at regions with potential functional
relevance for prostate tumors. To address this question, weexamined the genomic context in which intratumoral heteroge-
neous CpG methylation most frequently occurred. Between
normal prostate epithelia from the same or different individuals,
DNA methylation variability was comparatively low and distrib-
uted homogeneously across the genome (Figure 4A). In
contrast, enhancer sites exhibited substantial DNA methylation
variability within tumors, whereas methylation at transcription
start sites (TSS) and CpG islands (CGIs) remained relatively
static during subclonal diversification. These observations are
exemplified at the MAPK3 locus, in which the regions with
enhancer-associated chromatin marks displayed high DNA
methylation variability whereas methylation at the TSS and
CGIs remained relatively stable (Figure 4B). To characterize po-
tential biological differences between static and variably methyl-
ated enhancer domains, we next examined the difference in
transcription factor (TF) occupancy between these two groups.
Five out of 65 TF motifs significantly enriched for variable over
static enhancer domain binding (p < 0.001) showed enrichment
in all five cases, including the androgen receptor (AR) response
element and/or half-site-binding motif (Figure 4C). Consistently,
enhancer domains bound by AR displayed significantly higher
intratumoral methylation ranges compared to AR binding or
enhancer regions alone (Figure 4D). Given the known impor-
tance of the AR in prostate tumorigenesis (Carver et al., 2011;
Wang et al., 2009; Weischenfeldt et al., 2013; Yu et al., 2010),
we further investigated the link between oncogenic TF binding
and DNA methylation heterogeneity. Oncogenic TF binding
was generally associated with low levels of DNA methylation
across all tumor regions. However, AR-binding sites frequently
deviated from that unmethylated state, whereas FOXA1- and
especially ERG-binding sites remained more static (Figure 4E).
These results demonstrate that the degree of intratumoral
DNA methylation variability strongly depends on the genetic
and epigenetic context of a locus. Furthermore, the preference
of DNA methylation variability at prostate-specific gene-regula-
tory elements shows how methylome data might complement
genetic information by serving as a proxy of regulatory activity
in tumor subclones.
DISCUSSION
In this study, we have shown the profound genetic and epige-
netic intratumor heterogeneity of advanced prostate cancer
that also affected known prostate cancer drivers and genes
of prognostic significance. Only a subset of aberrant DNA
methylation events were recurrently found across all tumor
regions, of which some coincided with transcriptional downre-
gulation in prostate cancer. Regardless of whether these ubiq-
uitous aberrant methylation events were already present in the
most recent common ancestor or arose independently in
distinct tumor subpopulations, our study suggests that the
epigenome continues to evolve in parallel to the acquisition of
driving and passenger copy-number mutations. Hence, we
were able to associate epigenetic aberrations with the com-
plex clonal genetic architecture of the tumors, confirming the
view on somatic DNA methylation as a persistent rather than
dynamically regulated modification (Shipony et al., 2014). This
approach also allowed us to infer clonal relationships betweenCell Reports 8, 798–806, August 7, 2014 ª2014 The Authors 801
Figure 3. The Life History of Five Aggressive Prostate Cancers
(A) Consensus phylogenies based on merged genetic and epigenetic distance matrices for cases 1–5. Tissue types from each individual are color coded with
green (NP), orange (PIN), blue (TU), and red (LNM). Copy-number profiles of specimens marked with a hash key are shown in (B) to illustrate convergent evolution
of copy-number states. Specimens marked with an asterisk were used to illustrate convergent evolution of methylation patterns (C).
(B) Copy-number profiles of tumor samples TU_8, TU_9, and TU_10 from case 4 for chromosomes 1–X. Gained chromosome 8 in TU_9 and TU_10 is highlighted
by red coloring.
(C) Convergent evolution of methylation patterns between metastasis 3 and tumor specimens 8 and 9 from case 4. Heatmap shows methylation of the CpG sites
(304 out of the 4,557 most variable CpGs) with a significantly lower methylation level (Benjamini-Hochberg-adjusted p value < 0.01) in LNM_3, TU_8, and TU_9
compared to the other specimens. Blue indicates low, and yellow represents high methylation level (0%–100%). Specimens are arranged as in Figure 1. Tissue
types are color coded with green (NP), orange (PIN), blue (TU), and red (LNM). Black asterisk denotes specimens with analogous methylation state.
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Figure 4. The Degree of Intratumoral Heterogeneous DNA Methylation Depends on the Genetic and Epigenetic Context of a Locus
(A) DNA methylation variability between normal prostate epithelia and within tumors 1–5. Intraindividual variability of normal prostates was assessed using
specimens NP, PIN_1, and PIN_2 from case 3 whereas interindividual variability was analyzed by comparing normal prostates from the five cases. The median
methylation variability (based on intraepithelial/tumoral range) of all analyzed CpG sites associated with indicated genomic contexts is shown by colors ranging
from green (0.05) to red (0.2). Enhancers were defined by chromatin immunoprecipitation sequencing signals of predictive chromatin marks (H3K27ac and/or
H3K4me1) or enhancer RNAs of the normal prostate gland. CGI, CpG islands; eRNA, enhancer RNA; TSS, transcription start site.
(B) Median intratumoral DNAmethylation variability (based on intratumoral range) between prostate cancer cases 1–5 for all analyzed CpG sites in a 62 kb region
including the MAPK3 gene locus. Green track denotes CpG islands, blue track indicates H3K4me1 peaks, and orange track displays H3K27ac domains.
(C) Transcription-factor-binding motifs (n = 65) showing significant (p < 0.001) enrichment for binding at variably methylated enhancer domains. Pie chart
indicates the number of cases a TF motif was found to be significantly enriched in. Enrichment in all five cases was observed for androgen receptor (AR), E2A
immunoglobulin-enhancer-binding factors E12/E47 (E2A), estrogen-related receptor alpha (ERRA), paired box protein 7 (PAX7), and zinc finger X-chromosomal
protein (ZFX).
(D) Intratumoral DNA methylation variability of all CpGs or CpG sites colocalizing with AR-binding sites, enhancer domains (H3K4me1), or both. Width of the
beanplot indicates CpG density, and white lines show median methylation variability (range). Differences between enhancer and AR-bound enhancer are sta-
tistically significant (Wilcox test; p = 4.97 3 1067).
(E) Median methylation variability (left) and median methylation levels (right) as a function of distance to AR- (green), FOXA1- (blue), or ERG- (red) binding sites in
LNCaP prostate cancer cells.primary tumor and metastatic subclones, which revealed the
broad diversity in metastatic origin and the associated genetic
and epigenetic alterations. Future studies applying multiregion
analysis on hundreds of different tumors and corresponding
metastases will allow generalization about how frequently the
described evolutionary patterns actually occur in patients. In
addition to providing information on the genetic clonal relation-
ships, DNA methylation adds information about regulatory ac-
tivity at important cis-regulatory elements (Feldmann et al.,
2013; Stadler et al., 2011), as we have demonstrated by cases
of convergent and metastasis-specific aberrant methylation, as
well as through identification of high epigenetic heterogeneity
at androgen-receptor-bound enhancer domains. Consequently,
deducing tumor evolution that is based on epigenomic data
does not only allow rapid and sensitive reconstruction of tumor
structure but could potentially provide information on the func-
tional state of tumor subclones and thereby assist in future clin-
ical decision making.EXPERIMENTAL PROCEDURES
Patient Material
Research using pseudomized human leftover tissue samples from routine
diagnosis is covered by the Hamburgisches Krankenhausgesetz (HmbKHG)
x12. The study protocol (PV3552) was approved by the Institutional Review
Board of the Aerztekammer Hamburg (Chair: Prof. T. Weber). Informed con-
sent was obtained from all subjects involved in this study. A total of five
prostate cancer patients were selected that had large unifocal prostate
cancers, adjacent high-grade PIN that was large enough to be separately
analyzed, and at least three nodal metastases measuring R1 cm. All pros-
tates from these patients had been prepared according to standard proto-
cols (Erbersdobler et al., 2002), including complete paraffin embedding of
the entire prostates. For selection of tumor regions, estimation of tumor
cellularity, and nucleic acid isolation, see the Supplemental Experimental
Procedures.DNA Methylation Profiling
Genome-wide DNA methylation was analyzed on Illumina HumanMethyla-
tion450 BeadChip arrays (Illumina). Methylation of tumor and normal prostateCell Reports 8, 798–806, August 7, 2014 ª2014 The Authors 803
samples was measured according to the manufacturer’s instruction at the
DKFZ Genomics and Proteomics Core Facility. Data were analyzed using
the RnBeads pipeline (http://rnbeads.mpi-inf.mpg.de/) as described in the
Supplemental Experimental Procedures.
Copy-Number Alterations Profiling
Copy-number alterations (CNAs) were interrogated from the Illumina Human-
Methylation450 BeadChip with the sum of the methylated and unmethylated
signal intensities (Sturm et al., 2012) as described in the Supplemental Exper-
imental Procedures.
Unsupervised Hierarchical Clustering
For hierarchical clustering of casewise intratumoral methylation levels, a
Euclidean distance calculation and Ward’s linkage was performed for the
top 1% of probes with the greatest difference between intratumoral maximal
and minimal methylation (range). Normal epithelia and normal-like PIN lesions
(2_PIN_1, 3_PIN_1, 3_PIN_2, 4_PIN_1, and 4_PIN_2) were excluded for the
calculation of intratumoral DNA methylation range.
Phylogenetic Reconstruction
Top 1% (n = 4,457) of CpG sites with the greatest intratumoral methylation
range were used to generate DNA methylation Euclidean distance matrices.
For the calculation of intratumoral DNA methylation range, normal epithelia
and normal-like PIN lesions (2_PIN_1, 3_PIN_1, 3_PIN_2, 4_PIN_1, and
4_PIN_2) were excluded. Methylation-based phylogenetic trees were inferred
by the minimal evolution method (Desper and Gascuel, 2002) using the fast-
me.bal function in the R package ape. CNA-based phylogenies were either
generated using TuMult (Letouze´ et al., 2010; parameters th.bkp = 2) or by
applying the minimal evolution algorithm on CNA Euclidean distance matrices
that were based on continuous log2 ratios of the intensities. For consensus
phylogenetic reconstruction, CNA and methylation distance matrices were
elementwise added after being divided by their medians and clonal relation-
ships were inferred by applying the minimal evolution algorithm on the merged
CNA and methylation distance matrices. Strength of support for clades on
phylogenetic trees was assessed by bootstrapping (1,000 bootstrap repli-
cates) using the boot.phylo function from the R package ape.
Correlation between Copy-Number Alteration and
Methylation Distances
Casewise Euclidean distance matrices were generated based on continuous
CNA log2 ratios of the intensities or the top 1% DNA methylation probes
with the highest casewise intratumoral variability (range), unless otherwise
stated. For the calculation of intratumoral DNA methylation range, normal
epithelia and normal-like PIN lesions (2_PIN_1, 3_PIN_1, 3_PIN_2, 4_PIN_1,
and 4_PIN_2) were excluded. Similarity was assessed by calculating the Pear-
son’s correlation coefficient between the genetic and epigenetic distance
matrices. Samplewise correlation was obtained by using the diagonal ele-
ments of the resulting correlation matrix. An empirical p value was generated
by comparing the mean of the correlation matrix diagonal elements to a null
distribution generated by permuting sample labels and repeating the steps
100,000 times.
Genomic Context
Exon, intron, and TSS coordinates for RefSeq genes were downloaded from
University of California, Santa Cruz. Promoters were defined as 1.5 kb up-
stream and 0.5 kb downstream of RefSeq TSS. CpG islands and shores
were defined by standard Illumina 450K annotation. Previously reported (Yu
et al., 2010) AR, ERG, FOXA1, and H3K4me1 peaks from LNCaP (H3K4me1
also VCaP) prostate cancer cells as well as LNCaP H3K27ac peaks (Hazelett
et al., 2014) were downloaded from (http://www.cistrome.org). Enhancers of
the primary prostate gland, defined by differential enhancer RNA expression
(Andersson et al., 2014), were downloaded from (http://enhancer.binf.ku.dk/
Pre-defined_tracks.html).
Motif Enrichment
Transcription factor motif enrichment was calculated using the Homer
software package (Heinz et al., 2010). CpGs colocalizing with H3K4me1804 Cell Reports 8, 798–806, August 7, 2014 ª2014 The Authorspeaks were extended by 100 bp in both directions. Motif enrichment for
variably methylated (above median methylation variability at H3K4me1
peaks) enhancer CpGs was calculated in the resulting 200 bp regions
against the statically methylated (below median methylation variability
at H3K4me1 peaks) CpG 200 bp regions using the CpG-normalization
option.
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